Article Text

PDF
Association of anti-cyclic citrullinated peptide antibodies with subclinical atherosclerosis in patients with rheumatoid arthritis
  1. R Gerli1,
  2. E Bartoloni Bocci1,
  3. Y Sherer2,
  4. G Vaudo3,
  5. S Moscatelli1,
  6. Y Shoenfeld2
  1. 1
    Rheumatology Unit, Department of Clinical & Experimental Medicine, University of Perugia, Italy
  2. 2
    Center for Autoimmune Diseases, Department of Medicine B, Chaim Sheba Medical Center, Tel-Hashomer, Israel
  3. 3
    Section of Internal Medicine and Angiology, Department of Clinical & Experimental Medicine, University of Perugia, Italy
  1. Professor Roberto Gerli, Rheumatology Unit, Department of Clinical & Experimental Medicine, University of Perugia, Policlinico di Monteluce, I-06122 Perugia, Italy; gerlir{at}unipg.it

Statistics from Altmetric.com

Rheumatoid arthritis (RA) is associated with increased mortality, predominantly due to accelerated atherosclerosis.1 Traditional cardiovascular disease (CVD) risk factors cannot fully account for this increased propensity and it seems that the sustained inflammatory state of RA represents a crucial element for enhanced atherosclerotic risk.1 2 In fact, CVD mortality in RA appears to be predicted by the level of disease activity and severity of joint damage and extra-articular manifestations.2 3 Some immunological markers, such as rheumatoid factor or antinuclear antibodies, are more often encountered in RA with extra-articular manifestations.4 Anti-cyclic citrullinated peptide (anti-CCP) antibodies have been shown to be highly specific for …

View Full Text

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.